China chip stocks rally on self-reliance bets, Nvidia scrutiny
Investing.com - Citizens JMP analyst reiterated a Market Perform rating on Inhibrx Biosciences (NASDAQ:INBX) following the company’s second quarter 2025 earnings report. The stock has shown remarkable momentum, delivering a 92% return over the past six months. InvestingPro analysis indicates the stock is trading above its Fair Value, with 12 additional key insights available to subscribers.
The research firm based its rating on a cash per share and platform value analysis of the biotechnology company, which reported its quarterly results on Thursday.
Inhibrx Biosciences announced it expects to release results from its ChonDRAgon clinical trial by late October 2025, representing a key milestone for the company’s development pipeline.
The company reported a cash position of $186.6 million, which Citizens JMP noted provides sufficient capital to continue developing its key drug candidates through important readouts expected in the fourth quarter of 2025.
These development programs include ozekibart (INBRX-109), a tetravalent DR5 agonist, and INBRX-106, a hexavalent OR40 agonist, both of which are advancing toward critical data announcements later this year. With a market capitalization of $338 million and trading near its 52-week high of $25.29, investors can access detailed financial analysis and real-time updates through InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.